Virtu Financial’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-17,404
Closed -$12K 2011
2026
Q1
$12K Sell
17,404
-25,734
-60% -$24K ﹤0.01% 1445
2025
Q4
$67K Buy
+43,138
New +$68.9K ﹤0.01% 1270
2024
Q1
Sell
-15,161
Closed -$71K 1843
2023
Q4
$71K Buy
+15,161
New +$59K 0.01% 1108
2022
Q4
Sell
-156,158
Closed -$1.01M 1966
2022
Q3
$1.01M Buy
156,158
+7,141
+5% +$39.8K 0.09% 200
2022
Q2
$705K Sell
149,017
-2,141
-1% -$10.5K 0.06% 285
2022
Q1
$1.06M Sell
151,158
-5,048
-3% -$34.5K 0.08% 211
2021
Q4
$1.59M Buy
156,206
+6,828
+5% +$73.3K 0.16% 127
2021
Q3
$1.82M Buy
+149,378
New +$2.25M 0.16% 111

Other funds holding MXCT

Virtu Financial's MXCT Position: Q2 2026 in Review

Virtu Financial sold out of MaxCyte (MXCT) in Q2 2026, closing a stake of 17,404 shares — an estimated $12K sold.

Virtu Financial first reported a position in MXCT in Q3 2021 and held it in 8 quarters. The position peaked at $1.82M in Q3 2021. 122 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • Virtu Financial reported no remaining MaxCyte position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 17,404 MaxCyte shares in Q2 2026, an estimated $12K.
  • Virtu Financial first reported a position in MaxCyte in Q3 2021 and held it in 8 quarters.
  • Virtu Financial's MaxCyte position peaked at $1.82M in Q3 2021.
  • 122 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.